NuGen Announces Completion of Product Training With Sol Millennium as European Markets Expand
NuGen Announces Completion of Product Training With Sol Millennium as European Markets Expand
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of January 30th, 2024, Sol-Millennium Medical Inc.'s ("Sol-M") global sales & marketing team has now completed their in-depth clinical training of NuGen's needle-free InsuJet medical device for sales and marketing throughout Europe.
安大略省多倫多--(Newsfile Corp.,2024 年 1 月 30 日)——NuGen Medical Devices Inc.(TSXV:NGMD)(”公司“或”NuGen“) 一家領先的皮下治療用無針設備開發商欣然宣佈,自1月30日起第四,2024 年,Sol-Millennium Medical Inc.s (”Sol-M“)全球銷售和營銷團隊現已完成了對NuGen無針InsuJet醫療設備的深入臨床培訓,用於在歐洲各地進行銷售和營銷。
Louise Cresswell, NuGen's VP of Sales & Marketing for the UK and clinical expert, provided specialized training to a group of seven Sol-M sales representatives and equipped them with the necessary tools to employ a detail-oriented and proficient sales strategy for the European markets.
NuGen英國銷售與營銷副總裁兼臨床專家路易絲·克雷斯韋爾爲七名Sol-M銷售代表提供了專業培訓,併爲他們配備了必要的工具,使他們能夠爲歐洲市場採用注重細節和熟練的銷售策略。
Training specifically included detailed instructions and hands-on training of NuGen's InsuJet needle-free device to facilitate sales as it pertains to the diabetic markets in France and Spain.
培訓特別包括NuGen的InsuJet無針設備的詳細說明和實踐培訓,以促進與法國和西班牙糖尿病市場相關的銷售。
"Well-attended sessions with very good interactions from Sol-M sales representatives enabled me to share our experiences, and clinician and patient feedback of the InsuJetTM system to help the Sol-M team to drive sales and product adoption in their target markets throughout Europe," commented Louise Cresswell, NuGen's VP of Sales & Marketing. "The engagement and outcome with Sol-M were overwhelmingly positive with fulfillment set to achieve and perhaps even exceed expectations. I am very, very pleased," said Creswell.
“Sol-M 銷售代表參與人數衆多,互動非常好,這使我能夠分享我們的經驗,以及臨床醫生和患者對 InsuJet 的反饋TM 該系統可幫助Sol-M團隊在整個歐洲的目標市場推動銷售和產品採用,“NuGen銷售與營銷副總裁路易絲·克雷斯韋爾評論道。“與Sol-M的參與和結果非常積極,成就感即將實現,甚至可能超過預期。我非常非常高興,“克雷斯韋爾說。
As planned, European order forecasts are to be received by NuGen from Sol-M in the coming weeks which is in keeping with expectations with first orders arriving before the end of Q1 2024.
按計劃,NuGen將在未來幾周內收到來自Sol-M的歐洲訂單預測,這符合預期,第一批訂單將在2024年第一季度末之前到達。
"In January this year, I personally met overseas with Liang Lin, CEO of Sol-M, and am pleased to report a very positive relationship that will continue to grow further. After in-depth sales, marketing, and promotion training with Sol-M, which took months to complete, we are delighted to now go to market with our co-branded InsuJet needle-free medical device and consumables," commented Ian Heynen, CEO. "As I stated earlier, 2024 will be a very busy year reporting commercial progress and wins in all three of our business verticals."
“今年1月,我親自在海外會見了Sol-M首席執行官林亮,並很高興地報告了一段非常積極的關係,這種關係將繼續進一步發展。經過對Sol-M的深入的銷售、營銷和促銷培訓(花了幾個月的時間才完成),現在我們很高興帶着我們的聯名InsuJet無針醫療設備和消耗品進入市場,“首席執行官伊恩·海寧評論道。“正如我之前所說,2024年將是非常繁忙的一年,報告我們所有三個垂直業務領域的商業進展和勝利。“
About Sol-M
關於 Sol-M
Sol-M, NuGen's distributor since July 2023 for InsuJet in Canada, Brazil, France and Spain (See NuGen signs $204M distribution agreement with global leader in the diabetic industry) are global leaders in the healthcare industry with five offices around the world. Sol-M is a high-growth global medical device company committed to improving the safety and well-being of healthcare workers and their patients with the design and development of innovative safety-engineered medical devices. Sol-M is one of the world's largest designers and distributors of needles, syringes and diabetic supplies, offering a broad portfolio of patented products with global brand recognition such as Sol-Care for safety sharps, Sol-M for conventional medical devices and Sol-Guard for immunization products.
Sol-M 是 NuGen 自 2023 年 7 月起在加拿大、巴西、法國和西班牙的 InsuJet 分銷商(見 NuGen與糖尿病行業的全球領導者簽署了2.04億美元的分銷協議)是醫療保健行業的全球領導者,在全球設有五個辦事處。Sol-M 是一家高增長的全球醫療器械公司,致力於通過設計和開發創新的安全工程醫療器械來改善醫護人員及其患者的安全和福祉。Sol-M是世界上最大的針頭、注射器和糖尿病用品的設計商和分銷商之一,提供廣泛的具有全球品牌知名度的專利產品組合,例如用於安全銳器的Sol-Care、用於傳統醫療器械的Sol-M和用於免疫產品的Sol-Guard。
About NuGen:
關於 NuGen:
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously.
NuGen 是用於皮下給藥的無針設備的領先開發商。
The Company is marketing and selling its next-generation InsuJet needle-free injection system designed to improve the lives of millions of diabetics.
該公司正在營銷和銷售其下一代InsuJet無針注射系統,旨在改善數百萬糖尿病患者的生活。
InsuJet is approved for sale in 42 countries around the world.
InsuJet 獲准在全球42個國家銷售。
For further information, please visit:
欲了解更多信息,請訪問:
Websites: and
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn:
網站:和
Instagram:@NuGenMD
推特:@NuGenMD
領英:
For further information, please contact:
欲了解更多信息,請聯繫:
Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com
託尼·迪·貝內代託
執行主席
(416) 791-9399
tony@nugenmd.com
Ian Heynen
CEO
(416) 560-1019
ian@nugenmd.com
伊恩·海寧
首席執行官
(416) 560-1019
ian@nugenmd.com
To arrange a media interview with NuGen, please contact:
如需安排 NuGen 的媒體採訪,請聯繫:
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Notice Regarding Forward-Looking Information:
關於前瞻性信息的通知:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
TSXV及其監管服務提供商(該術語在TSXV的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
本新聞稿包含適用的加拿大證券立法所指的 “前瞻性信息” 和 “前瞻性陳述”(統稱爲 “前瞻性陳述”)。除歷史事實陳述外,所有陳述均爲前瞻性陳述,基於截至本新聞發佈之日的預期、估計和預測。任何涉及對預測、期望、信念、計劃、預測、目標、假設、未來事件或績效的討論的陳述(通常但並非總是使用 “期望”、“不期望”、“預期” 或 “不預期”、“計劃”、“預算”、“預算”、“預期”、“預測”、“估計”、“相信” 或 “打算” 等詞語或此類詞語的變體)以及短語或陳述 “可能” 或 “可能”、“將”、“可能” 或 “將” 發生或實現的某些行動、事件或結果)不是陳述歷史事實,可能是前瞻性陳述。這些前瞻性陳述受各種風險和不確定性以及其他因素的影響,這些因素可能導致實際事件或結果與前瞻性信息中的預測存在重大差異。此處包含的前瞻性信息是截至本文發佈之日提供的,除非法律要求,否則公司不承擔更新或修改此類信息以反映新事件或情況的責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因